Japan · Delayed Price · Currency is JPY Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 3.52 trillion. The enterprise value is 3.97 trillion.
| Market Cap | 3.52T |
| Enterprise Value | 3.97T |
Important Dates
The last earnings date was Thursday, October 30, 2025.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -0.07% in one year.
| Current Share Class | 1.79B |
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 53.19% |
| Float | 1.75B |
Valuation Ratios
The trailing PE ratio is 28.27 and the forward PE ratio is 18.13. Astellas Pharma's PEG ratio is 0.33.
| PE Ratio | 28.27 |
| Forward PE | 18.13 |
| PS Ratio | 1.75 |
| PB Ratio | 2.18 |
| P/TBV Ratio | 22.23 |
| P/FCF Ratio | 9.61 |
| P/OCF Ratio | 8.80 |
| PEG Ratio | 0.33 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.10, with an EV/FCF ratio of 10.85.
| EV / Earnings | 31.81 |
| EV / Sales | 1.98 |
| EV / EBITDA | 7.10 |
| EV / EBIT | 10.86 |
| EV / FCF | 10.85 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.03 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 1.32 |
| Debt / FCF | 2.02 |
| Interest Coverage | 28.40 |
Financial Efficiency
Return on equity (ROE) is 7.95% and return on invested capital (ROIC) is 9.58%.
| Return on Equity (ROE) | 7.95% |
| Return on Assets (ROA) | 6.68% |
| Return on Invested Capital (ROIC) | 9.58% |
| Return on Capital Employed (ROCE) | 17.37% |
| Revenue Per Employee | 147.09M |
| Profits Per Employee | 9.15M |
| Employee Count | 13,643 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.32 |
Taxes
In the past 12 months, Astellas Pharma has paid 11.93 billion in taxes.
| Income Tax | 11.93B |
| Effective Tax Rate | 8.72% |
Stock Price Statistics
The stock price has increased by +24.93% in the last 52 weeks. The beta is 0.04, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.04 |
| 52-Week Price Change | +24.93% |
| 50-Day Moving Average | 1,693.00 |
| 200-Day Moving Average | 1,518.22 |
| Relative Strength Index (RSI) | 80.62 |
| Average Volume (20 Days) | 10,483,190 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of JPY 2.01 trillion and earned 124.87 billion in profits. Earnings per share was 69.49.
| Revenue | 2.01T |
| Gross Profit | 1.63T |
| Operating Income | 369.14B |
| Pretax Income | 136.80B |
| Net Income | 124.87B |
| EBITDA | 563.08B |
| EBIT | 369.14B |
| Earnings Per Share (EPS) | 69.49 |
Balance Sheet
The company has 287.05 billion in cash and 740.54 billion in debt, giving a net cash position of -453.49 billion or -253.17 per share.
| Cash & Cash Equivalents | 287.05B |
| Total Debt | 740.54B |
| Net Cash | -453.49B |
| Net Cash Per Share | -253.17 |
| Equity (Book Value) | 1.61T |
| Book Value Per Share | 900.19 |
| Working Capital | 43.38B |
Cash Flow
In the last 12 months, operating cash flow was 399.70 billion and capital expenditures -33.65 billion, giving a free cash flow of 366.05 billion.
| Operating Cash Flow | 399.70B |
| Capital Expenditures | -33.65B |
| Free Cash Flow | 366.05B |
| FCF Per Share | 204.36 |
Margins
Gross margin is 81.28%, with operating and profit margins of 18.39% and 6.22%.
| Gross Margin | 81.28% |
| Operating Margin | 18.39% |
| Pretax Margin | 6.82% |
| Profit Margin | 6.22% |
| EBITDA Margin | 28.06% |
| EBIT Margin | 18.39% |
| FCF Margin | 18.24% |
Dividends & Yields
This stock pays an annual dividend of 78.00, which amounts to a dividend yield of 3.97%.
| Dividend Per Share | 78.00 |
| Dividend Yield | 3.97% |
| Dividend Growth (YoY) | 5.41% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 106.09% |
| Buyback Yield | 0.07% |
| Shareholder Yield | 4.04% |
| Earnings Yield | 3.55% |
| FCF Yield | 10.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.
| Last Split Date | Mar 27, 2014 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Astellas Pharma has an Altman Z-Score of 2.17 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 6 |